Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Constellation Pharmaceuticals, Inc is a biotechnology business based in the US. Constellation Pharmaceuticals shares (CNST) are listed on the NASDAQ and all prices are listed in US Dollars. Constellation Pharmaceuticals employs 154 staff and has a market cap (total outstanding shares value) of USD$1.2 billion.
Our top pick for
Beginners
Our top pick for
Active investors
Our top pick for
Building a portfolio
52-week range | USD$17 - USD$50.9 |
---|---|
50-day moving average | USD$33.19 |
200-day moving average | USD$26.3827 |
Wall St. target price | USD$47.75 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-3.125 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -18.56% |
Return on equity TTM | -33.77% |
Profit margin | 0% |
Book value | $8.603 |
Market capitalisation | USD$1.2 billion |
TTM: trailing 12 months
There are currently 5.8 million Constellation Pharmaceuticals shares held short by investors – that's known as Constellation Pharmaceuticals's "short interest". This figure is 1.2% down from 5.9 million last month.
There are a few different ways that this level of interest in shorting Constellation Pharmaceuticals shares can be evaluated.
Constellation Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Constellation Pharmaceuticals shares currently shorted divided by the average quantity of Constellation Pharmaceuticals shares traded daily (recently around 464733.25301205). Constellation Pharmaceuticals's SIR currently stands at 12.45. In other words for every 100,000 Constellation Pharmaceuticals shares traded daily on the market, roughly 12450 shares are currently held short.
However Constellation Pharmaceuticals's short interest can also be evaluated against the total number of Constellation Pharmaceuticals shares, or, against the total number of tradable Constellation Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Constellation Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Constellation Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1769% of the tradable shares (for every 100,000 tradable Constellation Pharmaceuticals shares, roughly 177 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Constellation Pharmaceuticals.
Find out more about how you can short Constellation Pharmaceuticals stock.
We're not expecting Constellation Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Constellation Pharmaceuticals's shares have ranged in value from as little as $17 up to $50.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Constellation Pharmaceuticals's is 2.7672. This would suggest that Constellation Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.